Home > Insider Trading > Filing (0001140361-24-030232)

Filing Details

Accession Number:: 0001140361-24-030232
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-06-14 21:00:42
Reporting Period:: 2024-06-14

Accepted Time:: 2024-06-14 21:00:42
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1368514	Adma Biologics Inc.	ADMA	Biological Products, (No Disgnostic Substances) (2836)	562590442

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1542517	S Adam Grossman	C/O Adma Biologics, Inc. 465 State Route 17 Ramsey NJ 07446	President,Ceo, And Interim Cfo	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2024-06-14	460,000	$3.21	2,191,475	No	4	J	Direct
Common Stock	Disposition	2024-06-14	10,000	$0.00	2,181,475	No	4	G	Direct
Common Stock	Disposition	2024-06-14	100,000	$10.72	2,081,475	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	J	Direct
No	4	G	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,143,426	Indirect	See Footnote
Common Stock	580,957	Indirect	See Footnote

Footnotes

The shares were transferred by the reporting person in accordance with the terms of a court-approved divorce settlement agreement (the "Divorce Settlement").
The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
(continued from footnote 3) (iv) 170,157 unvested Time-Based RSUs granted on September 29, 2021, subject to time-based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;
(continued from footnote 4) and (vi) 727,533 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
The shares were transferred by the reporting person to a third party in connection with the Divorce Settlement.
These shares were sold by the reporting person in connection with the Divorce Settlement.
These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.
These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden.